RxDoctor Payments Data

David Macari, MD

Hematology & Oncology · Sylvania, OHNPI 1992116123

Payments from drug & device makers

$9,791in general payments, 2019–2025

Across 421 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$641
  • Bristol Myers Squibb$603
  • AstraZeneca$597
  • Incyte Corporation$348
  • Amgen$287
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$2,02521%
  • Travel & lodging$891%
  • Food & beverage$7,63778%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson21$2,495
Novartis35$641
Bristol Myers Squibb51$603
AstraZeneca(2 entities)33$597
Incyte Corporation16$348
Amgen15$287
Genentech USA, Inc.14$267
Astellas Pharma US Inc12$234
Gilead(2 entities)7$224
Daiichi Sankyo Inc.10$223
Pfizer12$223
E.r. Squibb & Sons, L.L.C.13$217
Eisai Inc.8$168
Beigene USA, Inc.6$158
Sanofi9$146
AbbVie6$133
Adaptive Biotechnologies Corporation7$133
Takeda Pharmaceuticals U.S.A., Inc.7$129
AVEO Pharmaceuticals, Inc.6$121
Blueprint Medicines Corporation6$119
Seagen Inc.7$117
G1 Therapeutics, Inc.6$111
Karyopharm Therapeutics Inc.5$110
Bayer6$102
Jazz Pharmaceuticals Inc.6$99
Merck5$92
Pharmacyclics LLC, An Abbvie Company5$84
Pharmaessentia USA Corporation4$83
Array Biopharma Inc5$80
Sobi, Inc4$75
Agios Pharmaceuticals, Inc.4$69
Sun Pharmaceutical Industries Inc.3$65
EMD Serono, Inc.3$65
GSK3$58
Regeneron Healthcare Solutions, Inc.3$57
Azurity Pharmaceuticals, Inc.2$55
Rigel Pharmaceuticals, Inc.3$53
Novocure Inc.3$53
Boehringer Ingelheim3$53
Pharmacosmos Therapeutics Inc.3$49
Tersera Therapeutics LLC3$48
Dendreon Pharmaceuticals LLC2$46
Stemline Therapeutics Inc.2$44
Shield Therapeutics Inc2$41
Genmab U.S., Inc.2$39
Mirati Therapeutics, Inc.1$39
Lilly USA, LLC2$37
Servier Pharmaceuticals LLC2$37
Morphosys, US Inc.2$36
Recordati_rare_diseases_inc.2$36
Exelixis Inc.2$35
Puma Biotechnology, Inc.2$31
Foundation Medicine, Inc.2$30
Lexicon Pharmaceuticals, Inc.2$27
Organon2$23
Blue Earth Diagnostics1$23
Tempus AI, Inc1$22
CTI Biopharma Corp.1$20
Acrotech Biopharma Inc.1$20
AMAG Pharmaceuticals, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,791 in reported general payments places this provider in the 50th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$163,485
Medicare patients
431
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide54$696,352
RevlimidLenalidomide37$638,059
VerzenioAbemaciclib43$634,949
LynparzaOlaparib31$419,890
JakafiRuxolitinib Phosphate24$413,570
CalquenceAcalabrutinib Maleate22$258,453
NubeqaDarolutamide19$238,447
ZejulaNiraparib Tosylate11$205,823
KisqaliRibociclib Succinate13$203,332
Abiraterone Acetate41$174,758
EliquisApixaban64$52,168
XareltoRivaroxaban11$6,040
Ondansetron Hcl57$4,458
Letrozole136$3,206
Anastrozole71$2,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza, Calquence$597$678,34353 claims
Bristol Myers SquibbRevlimid$603$638,05937 claims
Lilly USA, LLCVerzenio, Olanzapine$37$635,38854 claims
Incyte CorporationJakafi$348$413,57024 claims
BayerNubeqa$102$238,44719 claims
GSKZejula$58$205,82311 claims
NovartisKisqali$641$203,33213 claims
PfizerEliquis$223$52,16864 claims
Johnson & JohnsonXarelto$2,495$6,04011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →